Embecta (NASDAQ:EMBC) CFO Acquires $93,400.00 in Stock

Embecta Corp. (NASDAQ:EMBC) CFO Jacob Elguicze purchased 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was bought at an average price of $4.67 per share, for a total transaction of $93,400.00. Following the purchase, the chief financial officer directly owned 309,139 shares in the company, valued at $1,443,679.13. The trade was a 6.92% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Embecta Stock Up 8.5%

Shares of NASDAQ EMBC traded up $0.41 during trading on Thursday, reaching $5.16. The company had a trading volume of 659,113 shares, compared to its average volume of 1,586,592. Embecta Corp. has a 12-month low of $2.77 and a 12-month high of $15.55. The business’s 50-day moving average is $3.43 and its 200 day moving average is $6.46. The stock has a market cap of $292.08 million, a PE ratio of 3.48 and a beta of 0.81.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. The firm had revenue of $271.70 million for the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The business’s revenue for the quarter was down 8.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, analysts anticipate that Embecta Corp. will post 1.85 earnings per share for the current year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be given a dividend of $0.01 per share. The ex-dividend date of this dividend is Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.8%. Embecta’s dividend payout ratio is presently 2.70%.

Hedge Funds Weigh In On Embecta

Several hedge funds have recently modified their holdings of the stock. Larson Financial Group LLC boosted its position in shares of Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after acquiring an additional 1,574 shares during the last quarter. One Wealth Advisors LLC bought a new stake in Embecta in the 2nd quarter valued at $33,000. Tower Research Capital LLC TRC lifted its stake in Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after purchasing an additional 6,224 shares in the last quarter. Wexford Capital LP purchased a new stake in Embecta in the 3rd quarter worth $94,000. Finally, Humankind Investments LLC bought a new position in shares of Embecta during the 2nd quarter valued at about $111,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Weiss Ratings lowered Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Bank of America decreased their price objective on Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research note on Monday, May 18th. Three analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $11.00.

Key Stories Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Negative Sentiment: The lawsuit, filed in federal court in New Jersey, alleges that Embecta and certain executives misrepresented the commercial stability of the company’s insulin pen-needle business. The allegations concern investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, and have not been proven in court. EMBC Securities Lawsuit: Embecta Securities Fraud Class Action is Pending
• Negative Sentiment: A wave of investor-alert releases from SBS Law, Kaplan Fox, DJS Law, Rosen Law Firm, Hagens Berman, Faruqi & Faruqi and other firms highlights an August 17, 2026 deadline for investors to seek lead-plaintiff status. The repeated announcements increase the visibility of the legal issue and could raise concerns about potential financial, management and reputational costs for Embecta. Kaplan Fox Alerts Investors of a Securities Class Action Against Embecta
• Neutral Sentiment: The announcements primarily seek potential plaintiffs and do not represent a new court ruling, settlement or regulatory finding. Embecta’s previously reported quarterly results showed adjusted earnings and revenue above consensus, but revenue declined 8.1% year over year; the company’s FY 2026 earnings guidance remains $1.80–$1.90 per share.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.